This is a preview of subscription content, log in via an institution to check access.
Notes
following first-line treatment with paracetamol [acetminophen]
The study was supported by Eli Lilly and Company, US.
incremental cost-effectiveness ratio
Reference
Wielage RC, et al. The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective. Value in Health 16: 334-44, No. 2, Mar 2013. Available from: URL: http://dx.doi.org/10.1016/j.jval.2012.12.006
Rights and permissions
About this article
Cite this article
Duloxetine cost-effective choice for CLBP in the US. PharmacoEcon Outcomes News 676, 7 (2013). https://doi.org/10.1007/s40274-013-0321-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0321-x